NCT06592989View on ClinicalTrials.gov

A Clinical Study of Sorafenib Combined With Gefitinib for the Treatment of pNET

RecruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

September 30, 2026

Conditions
Pancreatic Neuroendocrine NeoplasmSorafenibGefitinib
Interventions
DRUG

sorafenib, gefitinib

Sofantinib: 250mg, QD, oral; Gefitinib: 250mg, QD, oral.

Trial Locations (1)

200080

RECRUITING

Shanghai General Hospital, Shanghai

All Listed Sponsors
lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER